SBC Medical (NASDAQ: SBC) CEO sells 3.1M shares in underwritten deal
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
SBC Medical Group Holdings Incorporated entered into an underwriting agreement for an underwritten secondary offering of 3,100,000 shares of its common stock by CEO and chairman Dr. Yoshiyuki Aikawa as selling stockholder. The underwriters also received a 45-day option to buy up to an additional 465,000 shares.
The offering closed on April 21, 2026. The company did not sell any shares in this transaction and did not receive any proceeds, as all shares were sold by the existing stockholder under its Form S-3 registration statement.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Secondary shares offered: 3,100,000 shares
Underwriters’ option: 465,000 shares
Warrant exercise price: $11.50 per share
+1 more
4 metrics
Secondary shares offered
3,100,000 shares
Common stock sold by CEO as selling stockholder
Underwriters’ option
465,000 shares
Additional common shares purchasable within 45 days
Warrant exercise price
$11.50 per share
Exercise price for listed redeemable warrants (SBCWW)
Par value per share
$0.0001
Par value of SBC common stock
Key Terms
underwriting agreement, selling stockholder, Registration Statement on Form S-3, emerging growth company, +1 more
5 terms
underwriting agreement financial
"entered into an underwriting agreement (the “Underwriting Agreement”)"
An underwriting agreement is a contract where a company selling new stocks or bonds hires financial firms to buy those securities and resell them to investors. It matters because the agreement sets the offering price, number of securities, fees and which party bears the risk if sales fall short—think of it as a promise that the sale will happen and a roadmap investors can use to understand how the new securities reach the market.
selling stockholder financial
"as selling stockholder (the “Selling Stockholder”)"
A selling stockholder is an individual or entity that owns shares of a company's stock and chooses to sell some or all of those shares to others. This often occurs when the owner wants to cash in on their investment or reduce their stake. For investors, understanding who the selling stockholder is can provide insights into potential changes in the company's ownership or market activity.
Registration Statement on Form S-3 regulatory
"pursuant to the Company’s Registration Statement on Form S-3"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
redeemable warrants financial
"Redeemable Warrants, each whole warrant exercisable for one share"
A redeemable warrant is a tradable right that lets its holder buy a company’s shares at a fixed price before a set date, but the issuer has the contract power to cancel (redeem) the warrant early under agreed terms. For investors this matters because early redemption can force decision-making, change the timing of when new shares might be created, and affect potential gains or dilution—much like a store coupon that the issuer can cancel by paying you off instead of letting you use it.
FAQ
What did SBC (SBC) disclose in this 8-K filing?
SBC Medical Group Holdings disclosed an underwriting agreement for a secondary offering of 3,100,000 common shares by its CEO as selling stockholder. The deal was executed through Maxim Group LLC and used an existing Form S-3 registration statement.
Who is the selling stockholder in SBC (SBC)’s underwritten offering?
The selling stockholder is Dr. Yoshiyuki Aikawa, SBC Medical Group Holdings’ CEO and chairman of the board. He entered the underwriting agreement with Maxim Group LLC for the sale of his SBC common shares under the company’s Form S-3 registration.
When did SBC (SBC)’s secondary offering close?
The underwritten secondary offering of SBC’s common stock closed on April 21, 2026. The transaction followed the April 19, 2026 underwriting agreement and was conducted pursuant to the company’s effective Form S-3 registration statement filed in December 2025.